AR055017A1 - Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos - Google Patents
Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacosInfo
- Publication number
- AR055017A1 AR055017A1 ARP050105493A ARP050105493A AR055017A1 AR 055017 A1 AR055017 A1 AR 055017A1 AR P050105493 A ARP050105493 A AR P050105493A AR P050105493 A ARP050105493 A AR P050105493A AR 055017 A1 AR055017 A1 AR 055017A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- alkylamino
- amino
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 31
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 150000002367 halogens Chemical group 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 7
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- -1 hydroxy, amino Chemical group 0.000 abstract 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 125000005241 heteroarylamino group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos, procesos para su preparacion, composiciones farmacéuticas que los contienen y uso del compuesto para la fabricacion de medicamentos. Estos compuestos son utiles para el tratamiento de enfermedades inflamatorias y alérgicas co o inflamacion del tracto gastrointestinal, enfermedades de la piel, respiratorias, hipertension y enfermedades del metabolismo oseo (como osteoporosis). Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) en donde m es 0, 1 o 2; R1 es halogeno, hidroxi, ciano, trifluorometilo, trifluorometoxi, C1-6 alquilo, C1-6 alcoxi, C2-6 alquenilo, C2-6 alquinilo, C2-6 alcanoílo, C1-6 alquiltio, C1-6 alquilsulfinilo, C1-6 alquilsulfonilo, hidroxi-C2-6 alcoxi, amino C2-6 alcoxi, ciano-C2-6 alcoxi, C1-6 alquilamino-C2-6 alcoxi, di-[C1-6 alquil]amino-C2-6 alcoxi, C1-6 alcoxi-C2-6 alcoxi, carbamoil-C1-6 alcoxi, N-C1-6 alquilcarbamoil-C1-6 alcoxi, amino-C1-6 alquilo, C1-6 alquilamino-C1-6 alquilo, di[C1-6 alquil] amino-C1-6 alquilo, carbamoil-C1-6 alquilo, N-C1-6 alquilcarbamoil-C1-6 alquilo, hidroxi-C2-6 alquilamino, ciano-C2-6 alquilamino, halogeno, C2-6 alquilamino, amino-C2-6 alquilamino, C1-6 alcoxi-C2-6 alquilamino, C1-6 alquilamino-C2-6 alquilamino, di-[C1-6 alquil]amino-C2-6 alquilamino, heteroarilo, heteroaril-C1-6-alquilo, heteroariloxi, heteroaril-C1-6 alcoxi, heteroarilamino, heterociclilo, heterociclil-C1-6 alquilo, heterocicliloxi, heterociclil-C1-6 alcoxi y heterociclilamino, y en donde cualquier grupo arilo, heteroarilo o heterociclilo en un sustituyente R1 puede tener opcionalmente 1 o 2 sustituyentes seleccionados entre hidroxi, halogeno, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C3-6 cicloalquilo, C3-6 cicloalquil-C1-6 alquilo, C3-6 cicloalquil-C1-6 alcoxi, C1-6 alcoxi, carboxi, C1-6 alcoxicarbonilo, C1-6 alcoxicarbonil-C1-6 alquilo, N-C1-6 alquilcarbamoílo, N,N-di-[C1-6 alquil]carbamoílo, C2-6 alcanoílo, amino, C1-6 alquilamino, di-[C1-6 alquil]amino, halogeno-C1- 6 alquilo, hidroxi-C1-6 alquilo, C1-6 alcoxi-C1-6 alquilo, ciano-C1-6 alquilo, carboxi C1-6 alquilo, amino-C1-6 alquilo, C1-6 alquilamino-C1-6 alquilo y di-[C1-6 alquil]amino-C1-6 alquilo, y en donde y cualquiera de los sustituyentes R1 definidos precedentemente que comprende un grupo CH2 que está unido a 2 átomos de C o un grupo CH3 que está unido a un átomo de C o de N puede tener opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes seleccionados entre halogeno, hidroxi, amino, trifluorometilo, trifluorometoxi, oxo, carboxi, carbamoílo, acetamido, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C3-6 cicloalquilo, C3-6 cicloalcoxi, C1-6 alcoxi, C1-6 alquilamino, di-[C1-6 alquil]amino, hidroxi-C1-6 alquilo, C1- 6 alcoxi-C1-6 alquilo, halogeno-C1-6 alquilo, C1-6 alcoxi-C2-6 alcoxi, C1-6 alcoxicarbonilo, carbamoílo, N- C1-6 alquilcarbamoílo, N,N-di-[C1-6 alquil]carbamoílo, C1-6 sulfonilo, C1-6 sulfamoílo, heteroarilo, heteroaril-C1-6 alquilo, heterociclilo y heterocicliloxi, y en donde cualquier grupo heterociclilo en un sustituyente R1 puede tener opcionalmente 1 o 2 sustituyentes oxo o tioxo; R2 es halogeno, trifluorometilo o C1-6 alquilo; R3 es H, halogeno, trifluorometilo, ciano o C1-6 alquilo; R4 es C3-6 cicloalquilo, C1-6 alquilo o heteroarilo, y R4 puede estar opcionalmente sustituido por uno o más sustituyentes seleccionados entre halogeno, hidroxi, amino, C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, C1-6 alcoxi, C1-6 alquilamino y di- [C1-6 alquil]amino; y R5 es H, halogeno, trifluorometilo, ciano o C1-6 alquilo; o su sal aceptable para uso farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0428326A GB0428326D0 (en) | 2004-12-24 | 2004-12-24 | Amide derivatives |
| GB0507513A GB0507513D0 (en) | 2005-04-14 | 2005-04-14 | Amide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055017A1 true AR055017A1 (es) | 2007-08-01 |
Family
ID=35840517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050105493A AR055017A1 (es) | 2004-12-24 | 2005-12-22 | Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7786115B2 (es) |
| EP (1) | EP1831174B1 (es) |
| JP (1) | JP4937135B2 (es) |
| KR (1) | KR20070095911A (es) |
| CN (1) | CN102516170A (es) |
| AR (1) | AR055017A1 (es) |
| AT (1) | ATE500227T1 (es) |
| AU (1) | AU2005317868B2 (es) |
| BR (1) | BRPI0519287A2 (es) |
| CA (1) | CA2589764A1 (es) |
| DE (1) | DE602005026703D1 (es) |
| IL (1) | IL183657A (es) |
| MX (1) | MX2007007424A (es) |
| MY (1) | MY140868A (es) |
| NO (1) | NO20073730L (es) |
| NZ (1) | NZ555768A (es) |
| RU (1) | RU2396259C2 (es) |
| TW (1) | TWI364415B (es) |
| UY (1) | UY29301A1 (es) |
| WO (1) | WO2006067444A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
| GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| GB0504019D0 (en) * | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| GB0516570D0 (en) * | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
| CN101506171A (zh) * | 2006-06-19 | 2009-08-12 | 阿斯利康(瑞典)有限公司 | 作为细胞因子介导的疾病的抑制剂的异喹啉衍生物及其用途 |
| US20080070918A1 (en) * | 2006-08-24 | 2008-03-20 | Huang Kenneth H | Dihydropyridazine, Tetrahydropyridine, Chromanone, and Dihydronaphthalenone Derivatives |
| NZ599199A (en) * | 2007-03-20 | 2013-10-25 | Celgene Corp | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| CL2008000973A1 (es) | 2007-04-05 | 2009-01-02 | Astrazeneca Ab | Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma. |
| JP5259739B2 (ja) * | 2008-02-05 | 2013-08-07 | エフ．ホフマン−ラ ロシュ アーゲー | 新規ピリジノン及びピリダジノン |
| JP5506776B2 (ja) | 2008-03-25 | 2014-05-28 | アフェクティス ファーマシューティカルズ アーゲー | 新規ｐ２ｘ７ｒ拮抗薬及びその使用法 |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2010118921A1 (en) | 2009-04-14 | 2010-10-21 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2011010131A1 (en) | 2009-07-21 | 2011-01-27 | Astrazeneca Ab | Compositions comprising an oxoisoquinoline methylbenzamide and a polymer |
| BR112012010752B1 (pt) * | 2009-11-05 | 2021-07-20 | University Of Notre Dame Du Lac | Compostos imidazo[1,2-a]piridina |
| EA201201548A1 (ru) | 2010-05-14 | 2013-05-30 | Эффектис Фармасьютиклз Аг | Новые способы получения p2x7r антагонистов |
| WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| PH12013501934A1 (en) | 2011-03-18 | 2022-04-08 | Bayer Ip Gmbh | N-(3-carbamoylphenyl)-1h-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests |
| WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5136461A (en) * | 1974-09-24 | 1976-03-27 | Grelan Pharmaceutical Co | 44 * 22 isokarubosuchiririiru * fuenirusakusanruinoseizoho |
| JPS5143766A (en) * | 1974-10-09 | 1976-04-14 | Grelan Pharmaceutical Co | 44 * 22 * 3*44 jihidoroisokarubosuchiririiru * * fuenirusakusanruino seizoho |
| ZA924666B (en) * | 1991-06-27 | 1993-12-24 | Takeda Chemical Industries Ltd | Heterocyclic compounds, their production and use |
| EP0590455B1 (en) * | 1992-09-28 | 2000-12-27 | Hoechst Aktiengesellschaft | Antiarrhythmic and cardioprotective substituted 1(2H)-isoquinolines, process for their production, medicament containing them and their use for the production of a medicament for combating heart failures |
| JP4619545B2 (ja) | 1999-03-17 | 2011-01-26 | アストラゼネカ アクチボラグ | アミド誘導体 |
| JP2002220386A (ja) * | 2000-10-02 | 2002-08-09 | Tanabe Seiyaku Co Ltd | ベンジルアミン誘導体、その製法およびその合成中間体 |
| GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| GB0516570D0 (en) | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
-
2005
- 2005-12-22 MY MYPI20056172A patent/MY140868A/en unknown
- 2005-12-22 EP EP05823612A patent/EP1831174B1/en not_active Expired - Lifetime
- 2005-12-22 NZ NZ555768A patent/NZ555768A/en not_active IP Right Cessation
- 2005-12-22 RU RU2007130153/04A patent/RU2396259C2/ru not_active IP Right Cessation
- 2005-12-22 DE DE602005026703T patent/DE602005026703D1/de not_active Expired - Lifetime
- 2005-12-22 AU AU2005317868A patent/AU2005317868B2/en not_active Ceased
- 2005-12-22 BR BRPI0519287-0A patent/BRPI0519287A2/pt not_active IP Right Cessation
- 2005-12-22 US US11/793,781 patent/US7786115B2/en not_active Expired - Fee Related
- 2005-12-22 MX MX2007007424A patent/MX2007007424A/es active IP Right Grant
- 2005-12-22 WO PCT/GB2005/004984 patent/WO2006067444A1/en not_active Ceased
- 2005-12-22 UY UY29301A patent/UY29301A1/es not_active Application Discontinuation
- 2005-12-22 AT AT05823612T patent/ATE500227T1/de not_active IP Right Cessation
- 2005-12-22 KR KR1020077014184A patent/KR20070095911A/ko not_active Ceased
- 2005-12-22 AR ARP050105493A patent/AR055017A1/es not_active Application Discontinuation
- 2005-12-22 CN CN201110333201XA patent/CN102516170A/zh active Pending
- 2005-12-22 JP JP2007547641A patent/JP4937135B2/ja not_active Expired - Fee Related
- 2005-12-22 CA CA002589764A patent/CA2589764A1/en not_active Abandoned
- 2005-12-23 TW TW094146388A patent/TWI364415B/zh active
-
2007
- 2007-06-04 IL IL183657A patent/IL183657A/en not_active IP Right Cessation
- 2007-07-18 NO NO20073730A patent/NO20073730L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007130153A (ru) | 2009-02-20 |
| BRPI0519287A2 (pt) | 2009-01-06 |
| IL183657A0 (en) | 2007-09-20 |
| US7786115B2 (en) | 2010-08-31 |
| RU2396259C2 (ru) | 2010-08-10 |
| NZ555768A (en) | 2009-12-24 |
| AU2005317868A1 (en) | 2006-06-29 |
| JP4937135B2 (ja) | 2012-05-23 |
| CA2589764A1 (en) | 2006-06-29 |
| EP1831174B1 (en) | 2011-03-02 |
| IL183657A (en) | 2012-10-31 |
| HK1106245A1 (en) | 2008-03-07 |
| WO2006067444A1 (en) | 2006-06-29 |
| MY140868A (en) | 2010-01-29 |
| UY29301A1 (es) | 2006-07-31 |
| CN102516170A (zh) | 2012-06-27 |
| ATE500227T1 (de) | 2011-03-15 |
| JP2008525405A (ja) | 2008-07-17 |
| KR20070095911A (ko) | 2007-10-01 |
| TW200635901A (en) | 2006-10-16 |
| DE602005026703D1 (de) | 2011-04-14 |
| NO20073730L (no) | 2007-09-10 |
| TWI364415B (en) | 2012-05-21 |
| US20080146566A1 (en) | 2008-06-19 |
| MX2007007424A (es) | 2007-07-17 |
| EP1831174A1 (en) | 2007-09-12 |
| AU2005317868B2 (en) | 2009-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055017A1 (es) | Derivados de amida, un proceso para su preparacion, composicion farmaceutica y uso del compuesto para la fabricacion de farmacos | |
| AR046308A1 (es) | Derivados amida | |
| AU2020366257B2 (en) | Conjugate molecules | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| EA201000615A1 (ru) | Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы) | |
| ATE517882T1 (de) | Chinolinderivate | |
| WO2008125600A3 (en) | Pyrazole derivatives as p2x7 modulators | |
| RU2018106483A (ru) | Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr | |
| MX2010003346A (es) | Piperazino-dihidrotienopirimidinas sustituidas en heterociclo. | |
| EA201171333A1 (ru) | Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета | |
| BR0308784A (pt) | Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| PE20061397A1 (es) | Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos productos y metodos de preparacion | |
| GB0517191D0 (en) | Compounds | |
| CA3125731A1 (en) | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| AR067412A1 (es) | Moduladores de propiedades farmaceuticas de productos terapeuticos | |
| DE602007001463D1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| ZA202104940B (en) | Novel substituted sulfonylurea derivatives | |
| AR045694A1 (es) | Derivados de quinazolina para el tratamiento de enfermedades proliferativas, composiciones farmaceuticas que los contienen y proceso para su preparacion | |
| AR035945A1 (es) | Derivados de piperacina, su uso en la preparacion de medicamentos, procedimiento para la preparacion de dichos compuestos, composiciones farmaceuticas que comprenden dichos compuestos, y metodo para preparar dichas composiciones | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| AR051771A1 (es) | Acidos amino carboxilicos sustituidos | |
| AR046968A1 (es) | Derivados de amidas sustituidas | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |